NovaSignal Corp., a Los Angeles, CA-based medical technology and data company specializing in the assessment and management of brain health, raised $37m in Series C1 round of funding.
The round was led by Alpha Edison and Reimagined Ventures.
The company will use the capital to support its continued commercial expansion, delivery of product innovation, and new clinical trials to increase indications within and beyond stroke.
Led by Diane Bryant, Chair and CEO and Robert Hamilton, co-founder and Chief Scientific Officer, NovaSignal is a medical technology company whose FDA-cleared NovaGuide Intelligent Ultrasound combines non-invasive ultrasound, robotics, and artificial intelligence to assess cerebral hemodynamics in real time. Using cloud computing and data analytics, the company supports physicians in their clinical decision making in several neurological conditions including stroke, traumatic brain injury, and dementia.
Launched in April, the fully autonomous and cloud connected NovaSignal Platform is transforming stroke programs across the country by reducing the complexity of performing crucial cerebral assessments. The company also broadened its commercial footprint beyond the U.S. and Europe with a Health Canada license approval.
FinSMEs
28/09/2021